# Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

> **NCT02237196** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 121 (actual)

## Conditions studied

- Cat Allergy
- Cat Hypersensitivity

## Interventions

- **BIOLOGICAL:** AMG 157
- **BIOLOGICAL:** Cat Immunotherapy
- **BIOLOGICAL:** Cat Immunotherapy Placebo
- **BIOLOGICAL:** AMG 157 Placebo

## Key facts

- **NCT ID:** NCT02237196
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-03
- **Primary completion:** 2019-03-04
- **Final completion:** 2019-03-04
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2020-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02237196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02237196, "Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02237196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*